Registered Members Login:
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

4770 Pages (Click to Jump) V  « < 347 348 349 350 351 352 353 > »    
Reply to this topic

post Posted: May 13 2019, 10:20 AM
  Quote Post

Posts: 149
Thanks: 84

I think we trade $27 tonight. We shall see

Dr Wally is not a doctor at all. He's a dentist.
Johnny H
post Posted: May 11 2019, 11:29 AM
  Quote Post

Posts: 790
Thanks: 1364

In Reply To: xlnja's post @ May 11 2019, 08:22 AM

It all depends on if they go for a co-listing, or if they redomicle in the United States. If it's a co-listing, the symbol can stay the same. 5 letter tickers ending in "Y" are ADRs (ie Volkswagen VWAGY).

The important issue here is the continuous disclosure and reporting requirements, which are far stricter in the US than other markets.

As a pink sheet OTC, Clinuvel is exempt from SEC reporting.

With a NASDAQ co-listing, they are not exempt. No more cryptic newsletters. The stuff that they've gotten away with in the past won't fly with the SEC.

Clinuvel until my bowels release for the last time.

Said 'Thanks' for this post: xlnja  sharelooker  FarmaZutical  
post Posted: May 11 2019, 08:22 AM
  Quote Post

Posts: 57
Thanks: 111

In Reply To: xlnja's post @ May 11 2019, 07:51 AM

Think I found the answer...

While a lot of fanfare may occur when a stock is newly listed on an exchange, especially the NYSE, a new initial public offering (IPO) is not carried out. Instead, the stock simply goes from being traded through the OTC market to being traded on the exchange.

However, the stock symbol may change. A stock that moves from the OTC to Nasdaq often keeps its symbol. Contrarily, a stock that moves to the NYSE often must change its symbol, due to NYSE regulations that limit stock symbols to three letters. The OTC and Nasdaq both allow up to five letters.

Said 'Thanks' for this post: rabbitrun  Verharven  sharelooker  
Desert Rat
post Posted: May 11 2019, 08:12 AM
  Quote Post

Posts: 82
Thanks: 238

For anyone interested in peptide chemistry science, the 26th American Peptide Symposium (APS) will be held in Monterey, CA, June 22-27 (schedule link below).
Note that afamelanotide creator Tomi Sawyer, PhD (Merck and Co.) is chairing a session on "Peptide Drug Hunters:Taming Difficult Targets". There are also several "Vincent du Vigneaud honorary awards and sessions. Vincent du Vigneaud was the first to synthesize a cyclic peptide hormone, oxytocin, and he received the 1955 Nobel Prize in chemistry for that work. I checked the APS program and there is no mention of afamelanotide or other melanotropins as this is more of a basic science symposium and Clinuvel is quite distant from any shred of basic science. But none of the other peptide drug companies are presenting on marketed or almost-marketed drugs, so this is primarily for peptide chemists. In that regard, there is a tremendous amount of new information and new techniques, especially for "designing" peptides to specifically interact with hormone receptors at the molecular level.
Less than 2 months to wait now for the FDA decision- GLTA.

Said 'Thanks' for this post: juxtaposer  
post Posted: May 11 2019, 07:51 AM
  Quote Post

Posts: 57
Thanks: 111

In Reply To: johnnytech's post @ May 11 2019, 01:37 AM

With a NASDAQ listing, will the CLVLY ADRs all be converted to the new NASDAQ security? Or will they both continue to be traded?

post Posted: May 11 2019, 01:37 AM
  Quote Post

Posts: 454
Thanks: 886

In Reply To: MinusSinus's post @ May 10 2019, 07:31 PM

BNYM plays an important arbritage role. When the exchange rate between AUS / USD, AND, the market demand are out of sync, there is an arbritage opportunity. Doing arbritage helps stabilize the ADR and bring it into alignment with the parent stock. It guarantees they move in lock step.

Only BNYM is allowed to arbritage CLVLY because they were the original underwriter. Only they can remove shares from CLVLY and convert them to CUV, and vice versa. For that responsibility, they have the privilege of profiting on that discrepancy. This is an inherit function of investment banks that underwrite ADRs.

Now, moving on to the announcement, this is not the bank taking ownership stake in the company. This is an administrative task. Possibly related to an upcoming NASDAQ listing.

Said 'Thanks' for this post: xlnja  sharelooker

Share Cafe Sentifi Top themes and market attention on:

post Posted: May 10 2019, 10:37 PM
  Quote Post

Posts: 11
Thanks: 24

In Reply To: MinusSinus's post @ May 10 2019, 07:31 PM

Note 1:

Attached thumbnail(s)
Attached Image


post Posted: May 10 2019, 07:31 PM
  Quote Post

Posts: 23
Thanks: 72

In Reply To: sharelooker's post @ May 10 2019, 07:09 PM

Does BNYM plays a key role?

From what I read from the announcement, they are the issuer/depositary for the CLVLY ADRs - so my guess is they are preparing for higher demand of the ADRs.

Comments on Clinuvel on my value investing blog (English):

Said 'Thanks' for this post: Verharven  sharelooker  macgyver  arjan1972  DoktorBen  xray  odi01  Ray Cokes  
post Posted: May 10 2019, 07:09 PM
  Quote Post

Posts: 510
Thanks: 1881

In Reply To: royco's post @ May 10 2019, 05:45 PM

AVH also focuses on skin rejuvenation (cosmetic) and is a debt-free company. I think PW likes that wink.gif. The CEO has an excellent background (Novartis etc.) and much expertise in gene and cell therapy. I think a merger of CUV and AVH would make a lot of sense regarding long term sustainability. Does BNYM plays a key role?

Corporate presentation:

Said 'Thanks' for this post: wpw  Clinhope  odi01  
post Posted: May 10 2019, 05:45 PM
  Quote Post

Posts: 2,916
Thanks: 4530

In Reply To: Johnny H's post @ May 8 2019, 09:41 AM

German board digging deeper in avita.

Avita got approval from fda last September for the recell technology to treat burn wounds with spray on skin cells grown from own skin.
Results look amazing.

They plan to use the technology for vitiligo in a trial to start this year.
They combine therapy with melanocyte treatment in at least one patient.

It would be great to combine the vitiligo treatment trial.
Use the regenerative and melanogenesis features of afamelanotide.
A merger in the making?

It fits with the timing of the 2014 pre ema approval joint venture shake up.


Said 'Thanks' for this post: sharelooker  macgyver  odi01  Lisa0825  

4770 Pages (Click to Jump) V  « < 347 348 349 350 351 352 353 > » 

Back To Top Of Page
Reply to this topic

You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.